- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07373444
Cohorte de Envejecimiento Westlake (WeAC)
Cohorte de Envejecimiento de Westlake
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Descripción general del estudio
Estado
Descripción detallada
The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ju-Sheng Zheng, PhD
- Número de teléfono: 86-0571-86915303
- Correo electrónico: zhengjusheng@westlake.edu.cn
Ubicaciones de estudio
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310058
- Reclutamiento
- Hangzhou First People's Hospital
-
Contacto:
- Ju-Sheng Zheng, PhD
- Número de teléfono: 86-0571-86915303
- Correo electrónico: zhengjusheng@westlake.edu.cn
-
Hangzhou, Zhejiang, Porcelana, 310058
- Reclutamiento
- Hangzhou Third People's Hospital
-
Contacto:
- Peng Li, Master
-
Contacto:
- Yu Chen, Master
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
All participants must be Chinese residents, regardless of their ethnicity.
Descripción
Inclusion Criteria:
- Age between 55 and 90 years (inclusive) at baseline.
- Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
- Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
- MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
- Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
- Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.
Exclusion Criteria:
- Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
- Current use of psychoactive medications or any other drugs that may affect the study.
- Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
- Participants with any other diseases that may affect the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cognitive function
Periodo de tiempo: 48 months
|
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians. |
48 months
|
|
Gut microbiome
Periodo de tiempo: 48 months
|
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified. |
48 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Brain magnetic resonance imaging
Periodo de tiempo: 48 months
|
Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants. |
48 months
|
|
Positron emission tomography
Periodo de tiempo: 48 months
|
Assess the brain function and neurological disorders by positron emission tomography (PET). |
48 months
|
|
Brain images relevant inspections
Periodo de tiempo: 48 months
|
Other brain image relevant inspections required for study to measure brain structure and function of participants. |
48 months
|
|
Electroencephalogram
Periodo de tiempo: 48 months
|
Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking. |
48 months
|
|
Blood biochemical parameters
Periodo de tiempo: 48 months
|
Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer. |
48 months
|
|
Serum inflammatory factors
Periodo de tiempo: 48 months
|
Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants. |
48 months
|
|
Health and behavior monitoring
Periodo de tiempo: 48 months
|
Use fitness trackers to record the physiological and behavioral data of participants. |
48 months
|
|
Sleep data measurement
Periodo de tiempo: 48 months
|
Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality. |
48 months
|
|
Continuous glucose monitoring
Periodo de tiempo: 48 months
|
Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants. |
48 months
|
|
Environmental measurement
Periodo de tiempo: 48 months
|
Use the environmental monitoring device to measure various exposure factors in the participants' living environment. |
48 months
|
|
Multi-omics data
Periodo de tiempo: 48 months
|
Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc. |
48 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ju-Sheng Zheng, PhD, Westlake University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 20251023ZJS001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .